



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|---|-------------|----------------------|--------------------------|------------------------|
| 10/506,570 | 04/29/2005 | Stephen D. Harrison | PP19016.003 | 1325 |
| 7590 Chiron Corporation Intellectual Property R 338 PO Box 8097 Emeryville, CA 94662-8097 | | | EXAMINER LEWIS, AMY A | |
| | | | ART UNIT 1614 | PAPER NUMBER |
| | | | MAIL DATE 09/02/2008 | DELIVERY MODE PAPER |

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/506,570

Applicant(s)

HARRISON ET AL.

Examiner

Amy A. Lewis

Art Unit

1614

Period for Reply -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 06 June 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-56 is/are pending in the application.
- 4a) Of the above claim(s) 7, 11-48 and 51-56 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-6, 8-10, 49 and 50 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-850/8)
- 4) ☐ Interview Summary (PTO-413)
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____
- Paper No(s)/Mail Date 9/20/11/17/07, 5/15&2/24/06

DETAILED ACTION

Election/Restrictions

Applicant's election of Group I (claims 1-35 and 49-56) and the species: 1) compound of

GSK3 inhibitor compound of the invention, 6-[(2-[[6-(2,4-dichlorophenyl)-5-imidazolyl-
Example 5 2-pyridyl]amino]ethyl]amino]pyridine-3-carbonitrile (CT 99025)

(hereafter referred to as CT 99025); 2) absence of an additional agent; and 3) subcutaneous administration, in the reply filed on 6/6/2008 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election **without traverse** (MPEP § 818.03(a)).

Claims 7, 11-48 and 51-56 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to nonelected subject matter, there being no allowable generic or linking claim.

Claims 1-6, 8-10, 49 and 50 are examined as far as they read upon the elected species.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-6, 8-10, 49 and 50 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the treatment of ischemic brain injury, does not reasonably provide enablement for prevention of ischemic injury with the GSK3 inhibitor CT-99025 (Example 5). The specification does not enable any person skilled in the art to which it

pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims.

Factors to be considered in determining whether a disclosure would require undue experimentation have been summarized in *Ex parte Forman*, 230 USPQ 546 (BPAI 1986) and reiterated by the Court of Appeals in *In re Wands*, 8 USPQ2d 1400 at 1404 (CAFC 1988). The factors to be considered in determining whether undue experimentation is required include: (1) the quantity of experimentation necessary, (2) the amount or direction presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims.

The Board also stated that although the level of skill in molecular biology is high, the results of such experiments are unpredictable. While all of these factors are considered, a sufficient amount for a prima facie case are discussed below.

The nature of the invention & breadth of the claims:

The claims are directed to reducing and *preventing* ischemic injury by administering GSK3 inhibitors. Essentially, the claims include prevention of ischemic damage, including damage caused by a stroke.

The relative skill of those in the art:

The relative skill of those in the art is high, generally that of an M.D. and or M.D./Ph.D.

The presence or absence of working examples:

The specification at Example 5 demonstrates the treatment of transient focal cerebral ischemia due to stroke with CT 9025 in a rodent model (see pages 48-49 of the specification).

The state of the prior art & the predictability/unpredictability of the art:

The state of the prior art regarding the treatment of ischemic damage, such as that resulting from a transient ischemic stroke, is complex as well as unpredictable. As reviewed by Cheng et al. ("Neuroprotection for ischemic stroke," *NeuroRx* Jan 2004, Vol. 1, 36-45), there are a wide variety of factors involved in the pathology of stroke and the mechanism of nerve regeneration. Cheng et al. state the following:

The concept of neuroprotection mainly came from the studies of the pathology and pathophysiology of ischemic brain injury. It has been well documented that abrupt deprivation of oxygen and glucose to neuronal tissues elicits a series of pathological cascades, leading to spread of neuronal death. Of the numerous pathways identified, excessive activation of glutamate receptors, accumulation of intracellular calcium cations, abnormal recruitment of inflammatory cells, excessive production of free radicals, and initiation of pathological apoptosis are believed to play critical roles in ischemic damage, especially in the penumbral zone. (see page 36).

The state of the art regarding treatment of stroke is also very unpredictable, see Table 1 (on page 37) which summarizes a wide variety of clinical trials and the varied (poor) outcomes. Chen et al. even specifically state the "neuroprotective benefits from the laboratory bench to the emergency room has not been successful" (p. 36).

The specification does not enable a person skilled in the art to which is pertains to make or use the invention commensurate in scope with the claims. Applicants have failed to provide guidance and information sufficient to allow the skilled artisan to ascertain that the present active agent is effective for preventing ischemic damage, including such damage resulting from stroke. The limited enablement for treatment of transient ischemic stroke by administration of CT-99025 is noted but does not support a conclusion that all types of ischemic damage can be treated with the claimed active agents. Treatment and/or prevention of all known damage resulting from

ischemia cannot be accomplished with any reasonable certainty or without undue burden of experimentation.

In addition, for inventions in emerging and unpredictable technologies, or for inventions characterized by factors not reasonably predictable which are known to one of ordinary skill in the art, as is the case for prevention of ischemic damage due to a stroke, more evidence is required to show possession (MPEP § 2163). Therefore, absent a reasonable *a priori* expectation of success for preventing ischemic damage by administering CT-99025 after a stroke, the practice of the invention, as it is claimed in its current scope, would require an undue amount of experimentation because the specification provides inadequate guidance to do otherwise.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-6, 8-10, 49 and 50 are rejected under 35 U.S.C. 102(e) as being anticipated by U.S. Patent No. 7045519 (to Nuss et al.).

The applied reference has a common inventor(s) with the instant application. Based upon the earlier effective U.S. filing date of the reference, it constitutes prior art under 35 U.S.C. 102(e). This rejection under 35 U.S.C. 102(e) might be overcome either by a showing under 37 CFR 1.132 that any invention disclosed but not claimed in the reference was derived from the

inventor of this application and is thus not the invention "by another," or by an appropriate showing under 37 CFR 1.131.

Nuss et al. teach treatment of ischemia, cardiovascular disease (including stroke and cerebral ischemia), traumatic brain injury with GSK3 inhibitors. The reference teaches the instantly claimed compound CT-99025 and methods of synthesizing, and its GSK3 inhibitory activity (see Example 212 at col. 182). Administration, including by subcutaneous administration, of the GSK3 inhibitors (including CT-99025 as it is specifically enumerated in the Example 212) is taught to be useful for treatment of patients in need of treatment for inhibiting GSK3 activity thereof. See: abstract; col. 1, lines 14-27; claims 1, and 37-44; col. 210-224.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-6, 8-10, 49 and 50 are rejected under 35 U.S.C. 103(a) as being obvious over U.S. Patent No. 7045519 (to Nuss et al.).

The applied reference has a common inventor(s) with the instant application. Based upon the earlier effective U.S. filing date of the reference, it constitutes prior art only under 35 U.S.C. 102(e). This rejection under 35 U.S.C. 103(a) might be overcome by: (1) a showing under 37 CFR 1.132 that any invention disclosed but not claimed in the reference was derived from the inventor of this application and is thus not an invention "by another"; (2) a showing of a date of invention for the claimed subject matter of the application which corresponds to subject matter disclosed but not claimed in the reference, prior to the effective U.S. filing date of the reference under 37 CFR 1.131; or (3) an oath or declaration under 37 CFR 1.130 stating that the application and reference are currently owned by the same party and that the inventor named in the application is the prior inventor under 35 U.S.C. 104, together with a terminal disclaimer in accordance with 37 CFR 1.321(c). This rejection might also be overcome by showing that the reference is disqualified under 35 U.S.C. 103(c) as prior art in a rejection under 35 U.S.C. 103(a). See MPEP § 706.02(I)(1) and § 706.02(I)(2).

Nuss et al. teach treatment of ischemia, cardiovascular disease (including stroke and cerebral ischemia), traumatic brain injury with GSK3 inhibitors. The reference teaches the instantly claimed compound CT-99025 and methods of synthesizing, and its GSK3 inhibitory activity (see Example 212 at col. 182). Administration, including by subcutaneous administration, of the GSK3 inhibitors (including CT-99025 as it is specifically enumerated in the Example 212) is taught to be useful for treatment of patients in need of treatment for inhibiting GSK3 activity thereof. See: abstract; col. 1, lines 14-27; claims 1, and 37-44; col. 210-224. It would have been obvious to one of ordinary skill in the art at the time the invention was made to use the claimed compound (CT-99025) to treat ischemic damage (including that caused by a stroke), having been taught by Nuss et al. that inhibition of GSK3 is useful in the treatment of ischemic damage, and that the claimed compound has such inhibitory activity.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-6, 8-10, 49 and 50 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 39-44 of U.S. Patent No. 7045519 (to Nuss et al.). Although the conflicting claims are not identical, they are not patentably distinct from each other because both are directed to inhibition of GSK3 with the compound CT-99025 and treatment of ischemic damage in a subject by such inhibition.

Conclusion

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

- U.S. Patent No. 6489344 is considered to be an equivalent teaching to U.S. Patent No. 7045519.

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy A. Lewis whose telephone number is 571-272-9032. The examiner can normally be reached on Monday-Friday 9am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Amy A Lewis/
Examiner, Art Unit 1614

/Ardin Marschel/
Supervisory Patent Examiner, Art Unit 1614